Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Total Non-Current Liabilities (2019 - 2025)

4D Molecular Therapeutics (FDMT) has disclosed Total Non-Current Liabilities for 7 consecutive years, with $60.9 million as the latest value for Q4 2025.

  • Quarterly Total Non-Current Liabilities rose 23.38% to $60.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $60.9 million through Dec 2025, up 23.38% year-over-year, with the annual reading at $60.9 million for FY2025, 23.38% up from the prior year.
  • Total Non-Current Liabilities for Q4 2025 was $60.9 million at 4D Molecular Therapeutics, up from $54.9 million in the prior quarter.
  • The five-year high for Total Non-Current Liabilities was $60.9 million in Q4 2025, with the low at $12.4 million in Q2 2021.
  • Average Total Non-Current Liabilities over 5 years is $34.9 million, with a median of $30.8 million recorded in 2022.
  • Peak annual rise in Total Non-Current Liabilities hit 143.15% in 2022, while the deepest fall reached 11.57% in 2022.
  • Over 5 years, Total Non-Current Liabilities stood at $34.3 million in 2021, then decreased by 11.57% to $30.3 million in 2022, then rose by 5.01% to $31.8 million in 2023, then skyrocketed by 55.18% to $49.4 million in 2024, then grew by 23.38% to $60.9 million in 2025.
  • According to Business Quant data, Total Non-Current Liabilities over the past three periods came in at $60.9 million, $54.9 million, and $52.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.